Drug candidate offers hope of vocal improvement for ADNP syndrome

| November 16, 2018

article image
Activity-dependent neuroprotective protein (ADNP) syndrome is a rare genetic condition that causes developmental delays, intellectual disability and autism spectrum disorder symptoms in thousands of children worldwide. There is no known remedy for the disorder. Fortunately, scientists at Tel Aviv University (TAU) have identified a drug candidate – CP201, also known as NAP – that may help to improve the vocal communication abilities that are underdeveloped in such patients.

Spotlight

Zenith Healthcare Communications Ltd

Zenith Healthcare Communications Ltd (UK), provides its clients with an unusually nice dilemma: to either pay less for the same tactical mix OR do more with the same budget, while at the same time reassuring all within the team have a minimum of 10 years’ experience to allow quality levels to be maintained or even improved upon.

OTHER ARTICLES

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | March 11, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 11, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

The Future of Pharma Beyond Blockbusters

Article | March 11, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

Spotlight

Zenith Healthcare Communications Ltd

Zenith Healthcare Communications Ltd (UK), provides its clients with an unusually nice dilemma: to either pay less for the same tactical mix OR do more with the same budget, while at the same time reassuring all within the team have a minimum of 10 years’ experience to allow quality levels to be maintained or even improved upon.

Events